Research Topics
| AUGUSTUS RUSHSummaryAffiliation: University of Texas Southwestern Medical Center Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
[Vagus nerve stimulation. A potential therapy for chronic/recurrent depression?]A J Rush
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Fortschr Neurol Psychiatr 70:297-302. 2002..Ongoing studies will have to better establish its acute and longer-term efficacy, and specific indications in the treatment of depression...- Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trialA John Rush
Department of Psychiatry, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
Biol Psychiatry 58:347-54. 2005..Vagus nerve stimulation (VNS) alters both concentrations of neurotransmitters or their metabolites and functional activity of central nervous system regions dysregulated in mood disorders. An open trial has suggested efficacy... - Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic studyA John Rush
Department of Psychiatry, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
Biol Psychiatry 58:355-63. 2005..The need for effective, long-term treatment for recurrent or chronic, treatment-resistant depression is well established... 
Major depression symptoms in primary care and psychiatric care settings: a cross-sectional analysisBradley N Gaynes
Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7160, USA
Ann Fam Med 5:126-34. 2007....- The varied clinical presentations of major depressive disorderA John Rush
Department of Clinical Science and Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390 9086, USA
J Clin Psychiatry 68:4-10. 2007..This article provides a brief review of the status of several of the most common subtypes in terms of their clinical features, biological correlates, course of illness, and treatment implications... - Texas Medication Algorithm Project, phase 3 (TMAP-3): rationale and study designA John Rush
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, 75390 9086, USA
J Clin Psychiatry 64:357-69. 2003..Analyses were based on hierarchical linear models designed to test for initial changes and growth in differences between ALGO and TAU patients over time in this matched clinic design... - Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depressionA John Rush
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390 9086, USA
N Engl J Med 354:1231-42. 2006..After unsuccessful treatment for depression with a selective serotonin-reuptake inhibitor (SSRI), it is not known whether switching to one antidepressant is more effective than switching to another... - An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial reportA John Rush
Department of Psychiatry, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390 9086, USA
Biol Psychiatry 59:493-501. 2006..This report compares the performance of these three versions of the QIDS and the 17-item Hamilton Rating Scale for Depression (HRSD17)... - Sequenced treatment alternatives to relieve depression (STAR*D): rationale and designA John Rush
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9086, USA
Control Clin Trials 25:119-42. 2004..Participants with an adequate symptomatic response may enter the 12-month naturalistic follow-up phase with brief monthly and more complete quarterly assessments... - Does pretreatment insomnia or anxiety predict acute response to bupropion SR?A John Rush
Department of Psychiatry, The University of Texas Southwestern Medical Center, Dallas, TX 75390 9086, USA
Ann Clin Psychiatry 17:1-9. 2005..This retrospective analysis was conducted to determine whether pretreatment levels of insomnia or anxiety were associated with likelihood of or time to antidepressant response with bupropion sustained release (SR)... - Comorbid psychiatric disorders in depressed outpatients: demographic and clinical featuresA John Rush
Department of Psychiatry, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390 9086, USA
J Affect Disord 87:43-55. 2005..This study evaluated the clinical and sociodemographic features associated with various degrees of concurrent comorbidity in adult outpatients with nonpsychotic major depressive disorder (MDD)... - Self-reported depressive symptom measures: sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatientsA John Rush
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390 9086, USA
Neuropsychopharmacology 30:405-16. 2005..Global patient ratings such as the PGI-I, as opposed to specific item-based ratings, provide less valid findings... - Report by the ACNP Task Force on response and remission in major depressive disorderA John Rush
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390 9086, USA
Neuropsychopharmacology 31:1841-53. 2006..Research to evaluate these recommendations empirically is needed... - Toward an understanding of bipolar disorder and its originA John Rush
Department of Psychiatry, The University of Texas Southwestern Medical Center, Dallas 75390, USA
J Clin Psychiatry 64:4-8; discussion 28. 2003..To facilitate early diagnosis and effective management, clinicians should be aware of the risk factors, possible causes, and comorbidities of bipolar disease... 
Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment featuresA John Rush
Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390, USA
Arch Gen Psychiatry 65:870-80. 2008..Little is known about selecting among second-step medications for major depressive disorder after intolerance or lack of remission with an initial selective serotonin reuptake inhibitor...- Limitations in efficacy of antidepressant monotherapyA John Rush
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390 9066, USA
J Clin Psychiatry 68:8-10. 2007..Rates of remission for each consecutive monotherapy were increasingly lower, suggesting that a series of monotherapy options may not be the best treatment strategy for patients who are nonresponsive to an initial monotherapy... - Developing the evidence for evidence-based practiceA John Rush
Department of Clinical Sciences, The University of Texas Southwestern Medical Center at Dallas, Dallas, Tex 75390-9066, USA
CMAJ 178:1313-5. 2008 - Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D reportA John Rush
Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390 9086, USA
Am J Psychiatry 163:1905-17. 2006..This report describes the participants and compares the acute and longer-term treatment outcomes associated with each of four successive steps in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial... - Escitalopram in clinical practice: results of an open-label trial in a naturalistic settingA John Rush
University of Texas Southwestern Medical Center at Dallas, Department of Psychiatry, Dallas, Texas 75390 9086, USA
Depress Anxiety 21:26-32. 2005..Overall, 9% of patients discontinued due to adverse events. Escitalopram treatment was well tolerated and associated with robust response rates in a broadly representative population of depressed outpatients... - Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D reportMichael E Thase
Department of Psychiatry, University of Pittsburgh Medical Center, 3811 OHara St, Pittsburgh, PA 15213 2593, and Massachusetts General Hospital, USA
Am J Psychiatry 164:739-52. 2007..Cognitive therapy was compared with medication augmentation and switch strategies... - Clinical features of depressed outpatients with and without co-occurring general medical conditions in STAR*DWilliam R Yates
Department of Psychiatry, University of Oklahoma College of Medicine, Tulsa, OK 74135, USA
Gen Hosp Psychiatry 26:421-9. 2004..A significant percentage of patients with major depressive disorder (MDD) suffer from concurrent general medical conditions (GMCs)... - Acceptability of second-step treatments to depressed outpatients: a STAR*D reportStephen R Wisniewski
Department of Psychiatry, Epidemiology Data Center, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, and Clinical Psychopharmacology Unit, Massachusetts General Hospital, Boston, USA
Am J Psychiatry 164:753-60. 2007..This study sought to identify factors that affect patients' willingness to accept different second-step treatment approaches... - Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodesZiad Nahas
Brain Stimulation Laboratory, Department of Psychiatry, Medical University of South Carolina, Charleston, SC 29403, USA
J Clin Psychiatry 66:1097-104. 2005..We examined the effects of adjunctive VNS over 24 months in this cohort... - A direct comparison of presenting characteristics of depressed outpatients from primary vs. specialty care settings: preliminary findings from the STAR*D clinical trialBradley N Gaynes
Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7160, USA
Gen Hosp Psychiatry 27:87-96. 2005..The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study (http://www.star-d.org) provides a unique opportunity to provide this comparison for patients with a major depressive disorder (MDD) requiring treatment... - Sociodemographic, clinical, and treatment characteristics associated with worsened depression during treatment with citalopram: results of the NIMH STAR(*)D trialEdward S Friedman
Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
Depress Anxiety 26:612-21. 2009..But nonresponse can include depression that worsened over the course of treatment, an outcome that has received scant attention... - Insured and non-insured depressed outpatients: how do they compare?Ira M Lesser
Department of Psychiatry, Harbor UCLA Medical Center, The Los Angeles Biomedical Research Institute, Los Angeles, CA, USA
Ann Clin Psychiatry 19:73-82. 2007.... - Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combinationJohn Zajecka
Department of Psychiatry, Rush-Presbyterian-St. Luke's Medical Center, 1725 W. Harrison Street, Suite 955, Chicago, IL 60612, USA
J Clin Psychiatry 63:709-16. 2002..Treatment with nefazodone, CBASP, and combined treatment improved sexual interest/satisfaction, with greatest improvement observed with combined treatment... - Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: an examination of citalopram in the STAR*D studySidney Zisook
Department of Psychiatry, University of California, San Diego, San Diego VA Medical Center, San Diego, California, USA
J Affect Disord 117:63-73. 2009..The purpose of this study was to determine whether, and in whom, treatment of MDD is associated with increased or emergent SI... - Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depressionAlan J Gelenberg
Department of Psychiatry, Health Sciences Center, University of Arizona, PO Box 245002, Tucson, AZ 85724-5002, USA
Biol Psychiatry 54:806-17. 2003..8%). Somnolence was significantly greater among the patients taking active medication (15.4%), compared with placebo (4.6%). CONCLUSIONS: Nefazodone is well-tolerated and is an effective maintenance therapy for chronic forms of MDD... - Effect of age at onset on the course of major depressive disorderSidney Zisook
Department of Psychiatry, University of California, San Diego, CA 92093, USA
Am J Psychiatry 164:1539-46. 2007..This report assesses whether age at onset defines a specific subgroup of major depressive disorder in 4,041 participants who entered the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study... - The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 updateAlexander L Miller
Department of Psychiatry, The University of Texas Health Science Center at San Antonio, MC 7792, 7703 Floyd Curl Drive, San Antonio, TX 78229 3900, USA
J Clin Psychiatry 65:500-8. 2004..This article reports the recommendations developed in 2002 and 2003 by a group of experts, clinicians, and administrators... - Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorderLewis L Judd
Department of Psychiatry, University of California, San Diego, 9500 Gilman Dr, La Jolla, CA 92093 0603, USA
Am J Psychiatry 161:1864-71. 2004..Minor depressive disorder is both common and associated with significant psychosocial impairment. This study examined antidepressant treatment efficacy in a large group of patients with minor depressive disorder... - One-year clinical outcomes of depressed public sector outpatients: a benchmark for subsequent studiesA John Rush
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Biol Psychiatry 56:46-53. 2004..Results support the need for more powerful treatments and/or the better delivery of available treatments... - Do atypical antipsychotics effectively treat co-occurring bipolar disorder and stimulant dependence? A randomized, double-blind trialVicki A Nejtek
Department of Psychiatry, University of North Texas Health Science Center at Fort Worth, TX 76107, USA
J Clin Psychiatry 69:1257-66. 2008.... - Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combinationPhilip T Ninan
Department of Psychiatry, Emory University School of Medicine, Atlanta, GA 30329, USA
J Clin Psychiatry 63:434-41. 2002..Among patients with a concurrent anxiety disorder, nefazodone. either alone or in combination with CBASP, improves anxiety symptoms faster than CBASP alone, independent of depressive symptom reduction... - Differential effects of nefazodone and cognitive behavioral analysis system of psychotherapy on insomnia associated with chronic forms of major depressionMichael E Thase
Department of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, PA 15213 2593, USA
J Clin Psychiatry 63:493-500. 2002..As nefazodone-mediated blockade of serotonin-2 receptors may directly relieve insomnia associated with depression, we examined the more specific effects of CBASP and nefazodone, singly and in combination, on sleep disturbances... - Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) studyMaurizio Fava
Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA
Psychiatr Clin North Am 26:457-94, x. 2003..This article provides the overall rationale for STAR*D and details the rationale for key design, measurement, and analytic features of the study... - What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depressionBradley N Gaynes
Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA
Psychiatr Serv 60:1439-45. 2009..STAR*D demonstrated that inclusion of more real-world patients in clinical trials is both feasible and informative. Policy implications of the findings, as well as the study's limitations, are discussed... - Measuring use and cost of care for patients with mood disorders: the utilization and cost inventoryT Michael Kashner
Department of Clinical Sciences and Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Med Care 47:184-90. 2009..This article describes and tests the Utilization and Cost Inventory (UAC-I), a structured patient interview designed to measure costs of care when access to provider records is limited... - Factors that differentiate early vs. later onset of major depression disorderSidney Zisook
Department of Psychiatry, University of California, San Diego, San Diego VA Medical Center, 9500 Gilman Dr, 0603R, La Jolla, CA 92093, USA
Psychiatry Res 129:127-40. 2004..Thus, pre-adulthood onset MDD is a particularly severe and chronic condition... - A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depressionMark S George
Department of Psychiatry, Medical University of South Carolina, 67 President Street 502 N, Charleston, SC 29425, USA
Biol Psychiatry 58:364-73. 2005..To better understand these effects on long-term outcome, we compared 12-month VNS+TAU outcomes with those of a comparable TRD group... - Sex differences in depression symptoms in treatment-seeking adults: confirmatory analyses from the Sequenced Treatment Alternatives to Relieve Depression studySheila M Marcus
Department of Psychiatry, University of Michigan Medical School, Ann Arbor, MI 48105, USA
Compr Psychiatry 49:238-46. 2008..This article examines sex differences in terms of illness attributes in a cohort of 2541 outpatients from across the United States who enrolled in the Sequenced Treatment Alternatives to Relieve Depression study... - The Texas medication algorithm project: clinical results for schizophreniaAlexander L Miller
Department of Psychiatry, MS 7792, University of Texas Health Science Center at San Antionio, 7703 Floyd Curl Drive, San Antonio, TX 78229 3900, USA
Schizophr Bull 30:627-47. 2004..In secondary comparisons of ALGO with the second TAU group, the greater improvement in cognitive functioning was again noted, but the initial symptom difference was not significant... - Skating to where the puck is going to be: a plan for clinical trials and translation research in mood disordersEllen Frank
Department of Psychiatry, Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania 15213, USA
Biol Psychiatry 52:631-54. 2002..A rationale for the importance of each of these priorities is provided... - The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind trial of risperidone vs. quetiapinePaul A Nakonezny
Department of Clinical Sciences, Division of Biostatistics, The University of Texas Southwestern Medical Center, Dallas, TX 75235 8828, USA
J Sex Marital Ther 33:203-16. 2007..20). In this 6-week randomized double-blind trial, higher serum prolactin level was related to greater impairment of sexual functioning in male outpatients who were treated with risperidone, but not with quetiapine... - Factors associated with concomitant psychotropic drug use in the treatment of major depression: a STAR*D ReportRchard C Shelton
Department of Psychiatry, Vanderbilt University, Nashville, TN 37212, USA
CNS Spectr 14:487-98. 2009..Concomitant psychotropic medication (CPM) treatment is common in persons with major depression (MDD). However, relationships with patient characteristics and response to treatment are unclear... - Symptom features of postpartum depression: are they distinct?Ira H Bernstein
Department of Psychology, University of Texas at Arlington, Arlington, TX 75390 9086, USA
Depress Anxiety 25:20-6. 2008..These symptomatic differences between postpartum and other depressives suggest the need to include agitation/restlessness and impaired concentration/decision-making among screening questions for postpartum depression... - Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodiumRussell E Scheffer
Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390-8589, USA
Am J Psychiatry 162:58-64. 2005..Divalproex sodium alone (8-week trial) is not an effective treatment for ADHD in the context of bipolar disorder... - Genetic and clinical predictors of sexual dysfunction in citalopram-treated depressed patientsRoy H Perlis
Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA
Neuropsychopharmacology 34:1819-28. 2009..These hypothesis-generating analyses suggest the potential for glutamatergic treatment targets for sexual dysfunction during major depressive episodes... - Health-related quality of life in depression: a STAR*D reportElla J Daly
Department of Psychiatry, University of Texas Southwestern Medical School at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390 9119, USA
Ann Clin Psychiatry 22:43-55. 2010..This report examined the psychological, physical, and social domains in a large sample of outpatients who entered the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial... - Remission of maternal depression: relations to family functioning and youth internalizing and externalizing symptomsCynthia Ewell Foster
Department of Psychiatry, University of Michigan, Ann Arbor, MI 48105, USA
J Clin Child Adolesc Psychol 37:714-24. 2008..9% of the variance... - Depression outcomes of Spanish- and english-speaking Hispanic outpatients in STAR*DIra Lesser
Department of Psychiatry, Harbor UCLA Medical Center, Torrance, CA 90509, USA
Psychiatr Serv 59:1273-84. 2008.... - Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: results from STAR*DBradley N Gaynes
Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC, USA
J Gen Intern Med 23:551-60. 2008..Whether the acute outcomes of major depressive disorder (MDD) treated in primary (PC) or specialty care (SC) settings are different is unknown... - Diurnal mood variation in outpatients with major depressive disorder: implications for DSM-V from an analysis of the Sequenced Treatment Alternatives to Relieve Depression Study dataDavid W Morris
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390 9119, USA
J Clin Psychiatry 68:1339-47. 2007.... - Clinician ratings vs. global ratings of symptom severity: a comparison of symptom measures in the bipolar disorder module, phase II, Texas Medication Algorithm ProjectE Sherwood Brown
Department of Psychiatry, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, 75390-8849, Dallas, TX, USA
Psychiatry Res 117:167-75. 2003..Global assessments by patients or physicians only moderately or poorly reflected BPRS(24) scores. Itemized symptom measures to gauge severity of illness or change over time are preferred over patient or physician global judgments... - Psychosis in bipolar disorder: phenomenology and impact on morbidity and course of illnessPaul E Keck
Department of Psychiatry, University of Cincinnati College of Medicine, OH 45267-0559, USA
Compr Psychiatry 44:263-9. 2003..The lack of observable prognostic impact may have been, in part, due to the relatively high morbidity and poor functional outcome of a substantial portion of the total cohort... - Continuation treatment of chronic depression: a comparison of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combinationJames H Kocsis
Department of Psychiatry, Weill Cornell Medical College, New York, NY 10021, USA
Psychopharmacol Bull 37:73-87. 2003..COMB was associated with less symptom re-emergence during the continuation phase than either monotherapy, particularly for partial remitters... - Development of the Brief Bipolar Disorder Symptom Scale for patients with bipolar disorderEllen B Dennehy
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA
Psychiatry Res 127:137-45. 2004..The BDSS demonstrated superior sensitivity to symptom change, and an excellent level of agreement for classification of patients as either responders or non-responders with the BPRS24... - STAR*D: revising conventional wisdomA John Rush
Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, Texas, USA
CNS Drugs 23:627-47. 2009..Although switch and augmentation strategies could not be directly compared due to the equipoise stratified randomized design, the higher remission rates at step 2 with medication augmentation are intriguing and merit further study... - A quality improvement process for implementing the Texas algorithm for schizophrenia in OhioNaakesh A Dewan
Department of Psychiatry, University of Cincinnati, Cincinati, Ohio 45219, USA
Psychiatr Serv 54:1646-9. 2003..The results of the study may guide other states in their implementation of algorithms... - A descriptive analysis of minor depressionMark Hyman Rapaport
Department of Psychiatry, University of California, San Diego, School of Medicine, La Jolla, 92037, USA
Am J Psychiatry 159:637-43. 2002..The authors provide a detailed clinical description of minor depression: its symptoms, level of disability, stability, and relationship to patient and family history of major depressive disorder... - Remissions in maternal depression and child psychopathology: a STAR*D-child reportMyrna M Weissman
Department of Psychiatry, Columbia University and the New York State Psychiatric Institute, New York 10032, USA
JAMA 295:1389-98. 2006..Children of depressed parents have high rates of anxiety, disruptive, and depressive disorders that begin early, often continue into adulthood, and are impairing... - A psychometric evaluation of the CDRS and MADRS in assessing depressive symptoms in childrenShailesh Jain
Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
J Am Acad Child Adolesc Psychiatry 46:1204-12. 2007..This study compared the psychometric properties of the Children's Depression Rating Scale-Revised (CDRS-R) and the Montgomery-Asberg Depression Rating Scale (MADRS) in children with major depressive disorder... - Naturalistic study of the early psychiatric use of citalopram in the United StatesA John Rush
The University of Texas-Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, TX 75390-9086, USA
Depress Anxiety 16:121-7. 2002..8%, whereas those without such a history had a discontinuation rate of 13.3%. Citalopram administered at an average dose of 23.6 mg/day was associated with favorable outcomes and was generally well tolerated...
Research Grants
- Development of an Inventory of Depressive SymptomatologyAUGUSTUS RUSH; Fiscal Year: 2005..g., anxiety, irritability) (IDS-C and SR) that are in the public domain for use with patients across the age spans seen in practice and in research. ..